Search

Your search keyword '"Elida Dueñas Meza"' showing total 3 results
Start Over Author "Elida Dueñas Meza"
3 results on '"Elida Dueñas Meza"'

1. Sleep apnea and oxygen saturation in adults at 2640 m above sea level

Author

Maria Angelica Bazurto Zapata, Elida Dueñas Meza, Claudia Jaramillo, Dario Maldonado Gomez, and Carlos Torres Duque

Subjects
Sleep apnea, High altitude, Oxygen saturation, Psychology, BF1-990, Consciousness. Cognition, BF309-499
Abstract

Purpose: To describe the SpO2 in wakefulness, sleep and during the apnea–hypopnea in adults living in Bogotá, located at 2640 m above sea level. Methods: Descriptive observational study in adults referred for polysomnogram (PSG). A normal Apnea hypopnea index (AHI) was defined as ≤5 and obstructive sleep apnea (OSA) was classified as mild (AHI 5–15), moderate (AHI 15–30), and severe (AHI >30). T-test or ANOVA test for SpO2 differences between groups was used. Results: 1799 patients, 33% women. 222 (12.8%) did not have OSA (normal IAH), 268 (14.9%) mild OSA, 315 (17.5%) moderate ,and 993 (55.2%) severe. In all cases a low SpO2 (SpO2

Published
2014
Full Text
View/download PDF

3. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy

Author

Jorge F. Maspero, Elida Dueñas-Meza, Benjamin Volovitz, Carlos Pinacho Daza, Lajos Kosa, France Vrijens, and Jonathan A. Leff

Subjects
Cyclopropanes, Male, Cross-Over Studies, Time Factors, Adolescent, Anti-Inflammatory Agents, Beclomethasone, Administration, Oral, General Medicine, Acetates, Sulfides, Asthma, Treatment Outcome, Patient Satisfaction, Forced Expiratory Volume, Administration, Inhalation, Quinolines, Health Resources, Humans, Patient Compliance, Female, Anti-Asthmatic Agents, Child
Abstract

This 6-month, open-label extension study of a previously described base study compared oral montelukast with inhaled beclomethasone in terms of safety, forced expiratory volume in one second (FEV1) measurements, parent and patient satisfaction with treatment, asthma-related medical resource utilization, school absenteeism, and parental work loss in children with asthma. A total of 124 of 266 asthmatic children, 6 to 11 years of age, who enrolled in the base study entered a 6-month open-label extension study (74 boys, 50 girls) and were re-randomized (2:1 ratio) to receive once-daily oral montelukast (n = 83) or inhaled beclomethasone 100 mcg three times daily (n = 41). Children were evaluated in the clinic prior to re-randomization (Month 0) and at regular visits at 1, 3, and 6 months. Children and their parents showed a significantly higher overall satisfaction for montelukast at 6 months than for inhaled beclomethasone (p = 0.001 and p0.05, respectively). According to parents, montelukast was more convenient (p0.001), less difficult to use (p = 0.005), and was used as instructed more of the time (p = 0.006) compared with beclomethasone. Oral corticosteroid use was similar in the montelukast (13% of patients) and beclomethasone (17%) treatment groups. The montelukast treatment group was more adherent with their regimen than the inhaled beclomethasone treatment group; almost twice as many children on montelukast compared with inhaled beclomethasone were highly compliant (82% versus 45%). The two study groups were similar with respect to overall safety, change in FEV1, asthma-related medical resource utilization, school absenteeism, and parental work loss. Montelukast represents a safe and effective asthma treatment regimen to which children with asthma are more likely to adhere.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results